Medpace Holdings, Inc. $MEDP Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.8% in the third quarter, Holdings Channel.com reports. The fund owned 63,582 shares of the company’s stock after selling 3,889 shares during the period. Rhumbline Advisers’ holdings in Medpace were worth $32,691,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Wasatch Advisors LP boosted its holdings in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. lifted its position in shares of Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Medpace by 15.1% during the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after acquiring an additional 81,637 shares in the last quarter. Baillie Gifford & Co. grew its holdings in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its position in shares of Medpace by 11.4% during the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after purchasing an additional 45,435 shares during the period. Institutional investors own 77.98% of the company’s stock.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 59,025 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares in the company, valued at approximately $470,787,603.56. This trade represents a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 270,533 shares of company stock worth $163,122,826 over the last ninety days. 20.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MEDP. Truist Financial decreased their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday. Mizuho set a $582.00 price objective on shares of Medpace in a research note on Wednesday. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research report on Friday. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Finally, Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Four investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $487.36.

Medpace Price Performance

NASDAQ MEDP opened at $428.03 on Friday. The firm has a market capitalization of $12.15 billion, a price-to-earnings ratio of 27.98, a price-to-earnings-growth ratio of 2.05 and a beta of 1.42. The company has a 50 day simple moving average of $567.52 and a 200-day simple moving average of $538.35. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same quarter in the prior year, the business earned $3.67 EPS. The company’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.